IRHYTHM TECHNOLOGIES INC (IRTC) Stock Fundamental Analysis
USA - NASDAQ:IRTC - US4500561067 - Common Stock
177.4 USD
-3.09 (-1.71%)
177.4 USD
0 (0%)
Taking everything into account, IRTC scores 4 out of 10 in our fundamental rating. IRTC was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While IRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IRTC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year IRTC has reported negative net income.
IRTC had a positive operating cash flow in the past year.
In the past 5 years IRTC always reported negative net income.
IRTC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of IRTC (-5.17%) is better than 66.14% of its industry peers.
Looking at the Return On Equity, with a value of -42.22%, IRTC is in line with its industry, outperforming 51.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.17% | ||
| ROE | -42.22% | ||
| ROIC | N/A |
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IRTC's Gross Margin of 70.35% is amongst the best of the industry. IRTC outperforms 80.42% of its industry peers.
IRTC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for IRTC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
2. Health
2.1 Basic Checks
IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRTC has been increased compared to 1 year ago.
The number of shares outstanding for IRTC has been increased compared to 5 years ago.
The debt/assets ratio for IRTC is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.02 indicates that IRTC is not in any danger for bankruptcy at the moment.
IRTC's Altman-Z score of 4.02 is fine compared to the rest of the industry. IRTC outperforms 74.60% of its industry peers.
IRTC has a debt to FCF ratio of 20.01. This is a negative value and a sign of low solvency as IRTC would need 20.01 years to pay back of all of its debts.
The Debt to FCF ratio of IRTC (20.01) is better than 70.37% of its industry peers.
A Debt/Equity ratio of 5.32 is on the high side and indicates that IRTC has dependencies on debt financing.
With a Debt to Equity ratio value of 5.32, IRTC is not doing good in the industry: 87.83% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.32 | ||
| Debt/FCF | 20.01 | ||
| Altman-Z | 4.02 |
ROIC/WACCN/A
WACC8.4%
2.3 Liquidity
A Current Ratio of 4.63 indicates that IRTC has no problem at all paying its short term obligations.
IRTC has a better Current ratio (4.63) than 75.13% of its industry peers.
A Quick Ratio of 4.50 indicates that IRTC has no problem at all paying its short term obligations.
IRTC has a better Quick ratio (4.50) than 79.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.72% over the past year.
IRTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.45%.
Measured over the past years, IRTC shows a very strong growth in Revenue. The Revenue has been growing by 22.49% on average per year.
EPS 1Y (TTM)69.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
Revenue 1Y (TTM)25.45%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%30.74%
3.2 Future
The Earnings Per Share is expected to grow by 23.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.45% on average over the next years. This is quite good.
EPS Next Y52.36%
EPS Next 2Y35.84%
EPS Next 3Y30.55%
EPS Next 5Y23.66%
Revenue Next Year25.64%
Revenue Next 2Y21.24%
Revenue Next 3Y19.23%
Revenue Next 5Y18.45%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IRTC. In the last year negative earnings were reported.
Also next year IRTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRTC indicates a somewhat cheap valuation: IRTC is cheaper than 68.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 175.81 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IRTC's earnings are expected to grow with 30.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.84%
EPS Next 3Y30.55%
5. Dividend
5.1 Amount
IRTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
177.4
-3.09 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners110.74%
Inst Owner Change-0.84%
Ins Owners0.88%
Ins Owner Change-0.19%
Market Cap5.70B
Revenue(TTM)702.57M
Net Income(TTM)-51463000
Analysts85.45
Price Target197.02 (11.06%)
Short Float %8.15%
Short Ratio7.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.57%
Min EPS beat(2)34.09%
Max EPS beat(2)81.05%
EPS beat(4)4
Avg EPS beat(4)55.92%
Min EPS beat(4)4.68%
Max EPS beat(4)103.85%
EPS beat(8)5
Avg EPS beat(8)0.84%
EPS beat(12)6
Avg EPS beat(12)-2.6%
EPS beat(16)10
Avg EPS beat(16)2.7%
Revenue beat(2)2
Avg Revenue beat(2)3.79%
Min Revenue beat(2)2.36%
Max Revenue beat(2)5.22%
Revenue beat(4)4
Avg Revenue beat(4)2.75%
Min Revenue beat(4)1.42%
Max Revenue beat(4)5.22%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)8
Avg Revenue beat(12)1.03%
Revenue beat(16)10
Avg Revenue beat(16)0.93%
PT rev (1m)7.09%
PT rev (3m)32.54%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)4.22%
EPS NY rev (1m)0.08%
EPS NY rev (3m)11.29%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)6.67%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)4.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.11 | ||
| P/FCF | 175.81 | ||
| P/OCF | 77.15 | ||
| P/B | 46.76 | ||
| P/tB | 47.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.32
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)1.01
FCFY0.57%
OCF(TTM)2.3
OCFY1.3%
SpS21.87
BVpS3.79
TBVpS3.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.17% | ||
| ROE | -42.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.35% | ||
| FCFM | 4.61% |
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
F-Score6
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.32 | ||
| Debt/FCF | 20.01 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 199.56% | ||
| Cap/Sales | 5.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.63 | ||
| Quick Ratio | 4.5 | ||
| Altman-Z | 4.02 |
F-Score6
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)235.33%
Cap/Depr(5y)237.52%
Cap/Sales(3y)7.91%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
EPS Next Y52.36%
EPS Next 2Y35.84%
EPS Next 3Y30.55%
EPS Next 5Y23.66%
Revenue 1Y (TTM)25.45%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%30.74%
Revenue Next Year25.64%
Revenue Next 2Y21.24%
Revenue Next 3Y19.23%
Revenue Next 5Y18.45%
EBIT growth 1Y44.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year151.26%
EBIT Next 3Y48.71%
EBIT Next 5Y33.14%
FCF growth 1Y158.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y442.85%
OCF growth 3YN/A
OCF growth 5YN/A
IRHYTHM TECHNOLOGIES INC / IRTC FAQ
What is the ChartMill fundamental rating of IRHYTHM TECHNOLOGIES INC (IRTC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to IRTC.
What is the valuation status for IRTC stock?
ChartMill assigns a valuation rating of 2 / 10 to IRHYTHM TECHNOLOGIES INC (IRTC). This can be considered as Overvalued.
What is the profitability of IRTC stock?
IRHYTHM TECHNOLOGIES INC (IRTC) has a profitability rating of 2 / 10.
How financially healthy is IRHYTHM TECHNOLOGIES INC?
The financial health rating of IRHYTHM TECHNOLOGIES INC (IRTC) is 5 / 10.
What is the earnings growth outlook for IRHYTHM TECHNOLOGIES INC?
The Earnings per Share (EPS) of IRHYTHM TECHNOLOGIES INC (IRTC) is expected to grow by 52.36% in the next year.